Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 1;135(17):e188530.
doi: 10.1172/JCI188530. eCollection 2025 Sep 2.

Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares

James G Krueger  1 , Mrinal K Sarkar  2 , Mark G Lebwohl  3 , Akimichi Morita  4 , Kenneth Gordon  5 , Rachael Bogle  2 , Christopher Cole  2 , Anthony Coon  2 , Richard G Langley  6 , Richard B Warren  7 , Arash Mostaghimi  8 , Bruce Strober  9 , A David Burden  10 , Min Zheng  11 , Aaron R Mangold  12 , Milan J Anadkat  13 , Jonathan N Barker  14 , Joseph F Merola  15 , Lam C Tsoi  2 , Ming Tang  16 , Kolja Becker  17 , Denis Delic  17 , Christian Thoma  17 , Johann E Gudjonsson  18
Affiliations

Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares

James G Krueger et al. J Clin Invest. .

Abstract

People with generalized pustular psoriasis experience underlying skin inflammation, even in the absence of flares. Spesolimab treatment helps control the inflammation and prevent future flares.

Keywords: Dermatology; Inflammation; Neutrophils; Skin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The conflict-of-interest statement is available in the Supplemental Material.

Figures

Figure 1
Figure 1. Changes in proinflammatory gene expression during the study period.
Alternative biopsies are indicated by asterisks. The graph shows the gene expression of proinflammatory mediators in all 18 patients who participated in the biomarker study at all time points, including flare and postflare treatment and at the end of the study (week 48). Patients who had a complete series of biopsies throughout the studies are shown (Patients 1–7). One patient had more than 1 biopsy (Patient 6). DEFB4A, defensin β 4A; EoT, end of trial; LD, loading dose; NCF, neutrophil cytosolic factor; q12w, every 12 weeks; q4w, every 4 weeks; TNF, tumor necrosis factor.
See this image and copyright information in PMC

References

    1. Bachelez H, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981–983. doi: 10.1056/NEJMc1811317. - DOI - PubMed
    1. Morita A, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402(10412):1541–1551. doi: 10.1016/S0140-6736(23)01378-8. - DOI - PubMed
    1. Tauber M, et al. IL36RN mutations affect protein expression and function: a basis for genotype-phenotype correlation in pustular diseases. J Invest Dermatol. 2016;136(9):1811–1819. doi: 10.1016/j.jid.2016.04.038. - DOI - PubMed
    1. Jordan CT, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet. 2012;90(5):796–808. doi: 10.1016/j.ajhg.2012.03.013. - DOI - PMC - PubMed
    1. Mahil SK, et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol. 2016;136(11):2251–2259. doi: 10.1016/j.jid.2016.06.618. - DOI - PMC - PubMed

Substances